[Malignant intracranial lymphoma--clinical and patho-immunological study]

Area of Science:

• Neurology
• Oncology
• Immunology

Background:

• Primary intracranial malignant lymphoma (PIML) is a rare but aggressive brain tumor.
• Early diagnosis and understanding of PIML's clinical and immunological aspects are crucial.

Purpose of the Study:

• To conduct a clinical and patho-immunological study of PIML.
• To analyze patient demographics, clinical presentation, diagnostic methods, treatment outcomes, and survival rates.

Main Methods:

• Retrospective analysis of 15 PIML cases.
• Clinical evaluation, neuroimaging (CT scan, carotid angiography), and laboratory tests (gamma globulin, cellular immunity).
• Treatment included surgical removal and whole skull irradiation.

Main Results:

• Average age of patients was 45.2 years, with a male predominance (3:2 ratio).
• Common symptoms included hemiparesis (60%) and intracranial hypertension (45%).
• CT scans were highly effective for diagnosis and monitoring treatment response; radiosensitivity was confirmed.
• Laboratory findings indicated immune system alterations.
• Remission was achieved in 7 cases, with a 1-year survival rate of 35.7% and a 2-year survival rate of 14.3%.

Conclusions:

• PIML is characterized by specific clinical and immunological features.
• CT imaging is vital for diagnosis and assessing treatment efficacy.
• Despite aggressive treatment, PIML has a poor prognosis, highlighting the need for improved therapeutic strategies.